サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1771707

爪白癬の市場規模、シェア、動向分析レポート：タイプ別、治療法別、地域別、セグメント予測、2025年～2033年

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
爪白癬の市場規模、シェア、動向分析レポート：タイプ別、治療法別、地域別、セグメント予測、2025年～2033年
出版日: 2025年06月17日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

爪白癬市場の成長と動向：

Grand View Research社の最新レポートによると、世界の爪白癬市場規模は2033年までに57億4,000万米ドルに達すると予測されています。

同市場は2025年から2033年にかけてCAGR 4.7%で成長すると予測されています。爪白癬市場の成長は、治療に対する意識の高まりに助けられた爪白癬と慢性疾患の発生率の増加に起因します。感染症は心理的・社会的な制限につながり、個人の仕事や社会生活を制限する可能性があるため、感染症に苦しむ患者に効果的かつ効率的な治療を提供することが重要になり、市場の成長をさらに促進しています。

爪白癬の増加率は、市場全体の成長に寄与する主な要因です。この感染症は、しばしば爪白癬または真菌性爪感染症として知られ、米国では全人口の14％以上が罹患しています。しかし、爪白癬は性質上非常に伝染しやすく、加齢とともに発症リスクが高まるにもかかわらず、ほとんどの人は爪白癬がどれほど有害であるかを知らないです。

Global Nail Fungus Organizationのような国際的な組織は、世界中の公衆衛生当局やヘルスケア専門家と協力し、世界中で爪白癬に対する認識を高め、予防と治療の改善に努めています。このことは、治療薬の需要を促進すると予想されます。米国疾病予防管理センター（CDC）による「Think Fungus（真菌について考えよう）」などの政府のイニシアチブは、爪白癬などの真菌性疾患を患者の経過の早い段階で発見し、適切な治療を確実に行うことの重要性を強調しています。このため、爪白癬治療薬に対する需要が急増しており、同国の市場成長を牽引すると期待されています。

さらに、主なプレイヤーは、新規の爪白癬治療薬を開発し、市場での競争力を維持するために、共同研究やパートナーシップに注力しています。例えば、2022年8月、Moberg Pharma ABはPadagis Israel Agencies Ltd.と販売契約を締結し、イスラエルにおける爪白癬治療薬MOB-015の独占販売権をPadagisに与える見込みです。さらに、患者のコンプライアンス向上や投与量の削減といった懸念事項に対処するための技術革新が、市場の成長を促進すると予想されています。例えば、インタス・ファーマシューティカルズは2021年10月、世界初のスーパー・バイオアベイラブル・イトラコナゾールであるSB 100mgをItaspor-SB Forte/Subawinのブランド名で発売しました。この取り組みにより、患者のコンプライアンスが大幅に向上し、治療費が削減されることが期待されます。

爪白癬市場レポートハイライト

  • 遠位爪下爪白癬セグメントが2024年の市場を独占しており、これは有病率の増加と需要の高まりに対応するためのFDAによるジェネリック承認数に起因しています。
  • 外用剤セグメントは、使用と投与が容易であるため、患者の治療コンプライアンス向上につながり、予測期間中に最も速い成長率を示すと予想されます。
  • 競合各社は、競争力を強化し維持するために、資本集約的な特殊能力の獲得に注力しています。
  • 北米は2024年に最大の市場シェアを占めましたが、これはヘルスケアへのアクセスの良さ、幅広い対象人口の存在、治療の高い普及率に起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 爪白癬市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 爪白癬市場：タイプ別ビジネス分析

  • タイプ別市場シェア、2025年と2033年
  • タイプセグメントダッシュボード
  • 市場規模、予測、動向分析（タイプ別、2021～2033年）
  • 遠位側爪下型爪白癬
  • 白色表在型爪白癬
  • 近位側爪下型爪白癬
  • その他のタイプ

第5章 爪白癬市場：治療別ビジネス分析

  • 治療市場シェア、2025年と2033年
  • 治療セグメントダッシュボード
  • 市場規模と予測および動向分析（治療、2021～2033年）
  • 経口
  • 局所
  • その他

第6章 爪白癬市場：地域推定・動向分析

  • 地域別市場シェア分析、2025年および2033年
  • 地域市場ダッシュボード
  • 市場規模と予測動向分析、2021～2033年：
  • 北米
    • 国別、2021年～2033年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Bausch Health Companies Inc.
    • GSK plc
    • Abbott
    • Pfizer Inc
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Cipla
    • Merck &Co., Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global onychomycosis market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 6 North America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 8 North America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 9 U.S. onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 10 U.S. onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 11 Canada onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 12 Canada onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 13 Mexico onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 15 Europe onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 17 Europe onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 18 UK onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 19 UK onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 20 Germany onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 22 France onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 23 France onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 24 Italy onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 25 Italy onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 26 Spain onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 27 Spain onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 28 Norway onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 30 Denmark onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 31 Denmark onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 32 Sweden onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 33 Sweden onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 37 Japan onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 38 Japan onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 39 China onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 40 China onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 41 India onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 42 India onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 43 Australia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 44 Australia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 45 South Korea onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 46 South Korea onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 47 Thailand onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 48 Thailand onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 49 Latin America onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 51 Latin America onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 52 Brazil onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 53 Brazil onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 54 Argentina onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 55 Argentina onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Onychomycosis market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 59 South Africa onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 60 South Africa onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 63 UAE onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 64 UAE onychomycosis market, by treatment, 2021 - 2033 (USD Million)
  • Table 65 Kuwait onychomycosis market, by type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait onychomycosis market, by treatment, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Onychomycosis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Onychomycosis market dynamics
  • Fig. 12 Onychomycosis market: Porter's five forces analysis
  • Fig. 13 Onychomycosis market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Distal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 16 White Superficial Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 17 Proximal Subungual Onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 18 Other Types market, 2021 - 2033 (USD Million)
  • Fig. 19 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Topical market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Onychomycosis market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait onychomycosis market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework
目次
Product Code: GVR-4-68040-031-4

Onychomycosis Market Growth & Trends:

The global onychomycosis market size is anticipated to reach USD 5.74 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.7% from 2025 to 2033. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights:

  • Distal subungual onychomycosis segment dominated the market in 2024 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2024 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Onychomycosis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Onychomycosis Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Distal Subungual Onychomycosis
    • 4.4.1. Distal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.5. White Superficial Onychomycosis
    • 4.5.1. White Superficial Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.6. Proximal Subungual Onychomycosis
    • 4.6.1. Proximal Subungual Onychomycosis Market, 2021 - 2033 (USD Million)
  • 4.7. Other Types
    • 4.7.1. Other Types Market, 2021 - 2033 (USD Million)

Chapter 5. Onychomycosis Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2021 - 2033 (USD Million)
  • 5.5. Topical
    • 5.5.1. Topical Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Onychomycosis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Onychomycosis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Onychomycosis Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Onychomycosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Bausch Health Companies Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. GSK plc
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Abbott
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Bayer AG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Teva Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Cipla
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Novartis AG
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sun Pharmaceutical Industries Ltd.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives